Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 9 · newest first

  1. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid LeukemiasActa Haematologica · 2020
  2. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaBlood · 2019
  3. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical managementCancer · 2019
  4. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemiaCancer · 2019
  5. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaBlood · 2019
  6. Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing AnalysesBlood · 2019
  7. A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic LeukemiaBlood · 2019
  8. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid LeukemiaBlood · 2019
  9. Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)Blood · 2019
  10. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 StudyBlood · 2019
  11. Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of CyclesBlood · 2019
  12. Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)Blood · 2019
  13. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survivalAmerican Journal of Hematology · 2019
  14. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemiaBlood Advances · 2019
  15. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemiaCancer · 2019
  16. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationAmerican Journal of Hematology · 2019
  17. Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitorsAmerican Journal of Hematology · 2019
  18. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemiaBritish Journal of Haematology · 2019
  19. Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disordersHaematologica · 2019
  20. Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemiaCancer · 2019
  21. CPX-351 (vyxeos) in AMLLeukemia & lymphoma/Leukemia and lymphoma · 2019
  22. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United StatesCancer Medicine · 2019
  23. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatmentCancer Medicine · 2019
  24. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 studyCancer · 2019
  25. Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International CohortsJournal of Clinical Oncology · 2019
  26. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutationAmerican Journal of Hematology · 2019
  27. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemiaClinical Epigenetics · 2019
  28. Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemiaAmerican Journal of Hematology · 2019
  29. Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibAmerican Journal of Hematology · 2019
  30. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemiaCancer · 2019
  31. Ibrutinib and Venetoclax for First-Line Treatment of CLLNew England Journal of Medicine · 2019
  32. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapyLeukemia & lymphoma/Leukemia and lymphoma · 2019
  33. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsHaematologica · 2019
  34. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD 33 expression and in vitro response to targeted CD 33 therapyBritish Journal of Haematology · 2019
  35. Recent advances in the treatment of acute lymphoblastic leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2019
  36. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic LeukemiaBiology of Blood and Marrow Transplantation · 2019
  37. Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell TransplantationBiology of Blood and Marrow Transplantation · 2019
  38. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysisCancer · 2019
  39. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk diseaseAmerican Journal of Hematology · 2019
  40. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemiaLeukemia · 2019
  41. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyCancer · 2019
  42. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapyBlood Advances · 2019
  43. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIsBlood Advances · 2019
  44. Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndromeCancer · 2019
  45. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1‐mutated acute myeloid leukemiaAmerican Journal of Hematology · 2019
  46. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemiaCancer · 2019
  47. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNetBlood · 2019
  48. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapyBlood · 2019
  49. BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironmentJournal of Clinical Investigation · 2019
  50. Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapyOncotarget · 2019